eXoZymes, Inc. (EXOZ)
NASDAQ: EXOZ · Real-Time Price · USD
10.45
+0.44 (4.40%)
At close: Apr 8, 2026, 4:00 PM EDT
10.31
-0.14 (-1.34%)
After-hours: Apr 8, 2026, 4:00 PM EDT
eXoZymes Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
31
Market Cap
88.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 70.07K | 41.47K | 145.01% |
| Dec 31, 2022 | 28.60K | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 63.26M |
| BeyondSpring | 1.88M |
| Coeptis Therapeutics Holdings | 1.36M |
| NRx Pharmaceuticals | 1.23M |
| Fractyl Health | 3.00K |
EXOZ News
- 8 days ago - eXoZymes Provides Fourth Quarter and Full Year 2025 Update - Accesswire
- 14 days ago - eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026 - Accesswire
- 21 days ago - Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability - Accesswire
- 27 days ago - eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium - Accesswire
- 2 months ago - With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation - Accesswire
- 2 months ago - eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run - Accesswire
- 4 months ago - eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion - Accesswire
- 5 months ago - eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today - Accesswire